524636 — Oxygenta Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- IN₹4.45bn
- IN₹5.07bn
- IN₹1.09bn
- 18
- 12
- 92
- 34
Annual income statement for Oxygenta Pharmaceutical, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 520 | 605 | 310 | 396 | 1,093 |
| Cost of Revenue | |||||
| Gross Profit | 97.3 | 78.5 | -42.3 | -13.2 | 16.7 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 455 | 583 | 392 | 496 | 1,166 |
| Operating Profit | 65.1 | 22.1 | -82.6 | -99.4 | -73.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 31.4 | -4.89 | -114 | -139 | -144 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 29.3 | -6.1 | -116 | -34.8 | -103 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 29.3 | -6.1 | -116 | -34.8 | -103 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 29.3 | -6.1 | -116 | -34.8 | -103 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.872 | -0.759 | -7.81 | -1.1 | -2.81 |